May 10, 2019
Vifor Pharma’s Phase-II AMBER Study Meets Primary Endpoint
phase-II AMBER study whichdemonstrated that a significantly higher proportion of patients withresistant hypertension (RHTN) and chronic kidney disease (CKD) takingVeltassa® (patiromer) remained on spironolactone therapycompared to patients taking placebo at week 12.